AR132037A1 - Derivados de piridazinil amino como inhibidores del receptor alk5 - Google Patents
Derivados de piridazinil amino como inhibidores del receptor alk5Info
- Publication number
- AR132037A1 AR132037A1 ARP240100524A ARP240100524A AR132037A1 AR 132037 A1 AR132037 A1 AR 132037A1 AR P240100524 A ARP240100524 A AR P240100524A AR P240100524 A ARP240100524 A AR P240100524A AR 132037 A1 AR132037 A1 AR 132037A1
- Authority
- AR
- Argentina
- Prior art keywords
- alk5
- compounds
- receptor inhibitors
- amino derivatives
- alk5 receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En términos generales, la presente invención se refiere a compuestos que inhiben el receptor tipo I del factor de crecimiento transformante b (TGF b) (ALK5) (en adelante inhibidores de ALK5), a métodos para preparar dichos compuestos, a composiciones farmacéuticas que los contienen y al uso terapéutico que se hace de ellos. Los compuestos de la invención pueden ser útiles, por ejemplo, en el tratamiento de muchas enfermedades, trastornos o afecciones que se asocian con la vía de señalización ALK5. Un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23159706 | 2023-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132037A1 true AR132037A1 (es) | 2025-05-21 |
Family
ID=85461637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100524A AR132037A1 (es) | 2023-03-02 | 2024-03-01 | Derivados de piridazinil amino como inhibidores del receptor alk5 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4673214A1 (es) |
| KR (1) | KR20250153294A (es) |
| CN (1) | CN121039121A (es) |
| AR (1) | AR132037A1 (es) |
| AU (1) | AU2024229840A1 (es) |
| MX (1) | MX2025009709A (es) |
| WO (1) | WO2024180206A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4182308T3 (da) | 2020-07-15 | 2024-10-21 | Chiesi Farm Spa | Pyridazinylamino-derivater som ALK5-inhibitorer |
| TW202237119A (zh) * | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
| US20250011299A1 (en) * | 2021-09-21 | 2025-01-09 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
-
2024
- 2024-03-01 EP EP24707794.4A patent/EP4673214A1/en active Pending
- 2024-03-01 AU AU2024229840A patent/AU2024229840A1/en active Pending
- 2024-03-01 AR ARP240100524A patent/AR132037A1/es unknown
- 2024-03-01 WO PCT/EP2024/055317 patent/WO2024180206A1/en not_active Ceased
- 2024-03-01 KR KR1020257032317A patent/KR20250153294A/ko active Pending
- 2024-03-01 CN CN202480015173.2A patent/CN121039121A/zh active Pending
-
2025
- 2025-08-18 MX MX2025009709A patent/MX2025009709A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4673214A1 (en) | 2026-01-07 |
| MX2025009709A (es) | 2025-09-02 |
| KR20250153294A (ko) | 2025-10-24 |
| WO2024180206A1 (en) | 2024-09-06 |
| AU2024229840A1 (en) | 2025-10-09 |
| CN121039121A (zh) | 2025-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003012A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| AR121483A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| AR127050A1 (es) | Compuestos espirocíclicos | |
| MX2024003399A (es) | Derivados de piridazinil-amino como inhibidores del receptor del factor de crecimiento transformante beta tipo i (alk5). | |
| CL2022001337A1 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
| MX2023000521A (es) | Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5). | |
| DOP2025000013A (es) | Inhibidores de inflamasoma nlrp3 | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| ECSP22082217A (es) | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida | |
| MX2024003028A (es) | Derivados de 6 aza quinolina y usos relacionados. | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| CO2022015823A2 (es) | Derivados de n-(piperidin-4-il)benzamida de acción luminal | |
| AR132037A1 (es) | Derivados de piridazinil amino como inhibidores del receptor alk5 | |
| CO2024015686A2 (es) | Compuestos heteroaromáticos bicíclicos condensados y su uso en el tratamiento del cáncer | |
| AR131413A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| AR131414A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| AR131001A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| MX2022005843A (es) | Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5). | |
| AR132032A1 (es) | Derivados de piridazinil amino como inhibidores del receptor alk5 | |
| AR119280A1 (es) | Compuestos de 2,3-dihidroquinazolina como inhibidores nav1.8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |